Advertisement

$3.2 million NIH grant aims to correct diagnostic errors for breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In a new UCLA-led study, funded by a $3.2 million NCI grant, researchers will examine how perception and cognition interact in the interpretation of breast biopsy images. The aim is to improve physicians’ diagnostic skills and accuracy.

Joann Elmore, a UCLA Jonsson Comprehensive Cancer Center member and professor of medicine in the David Geffen School of Medicine at UCLA, is leading the five-year project which will study diagnostic errors made by residents in training as well as experienced pathologists.

“Pathologists want to be better at their job and find every suspicious lesion, but when they do make errors, it can be hard to know why,” said Elmore, who is also director of the UCLA National Clinician Scholars Program. “This project will use advanced eye-tracking techniques that measure exactly where the pathologist was looking during each case so that we can determine what is leading to diagnostic errors.”

Elmore’s previous research has identified high levels of disagreement and errors among physicians in the diagnosis of cancer.

Advertisement
Advertisement
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 
Advertisement
Advertisement